To show that the experiment can easily be performed by a collaboration of two laboratories we present here the results of an experiment that was conducted by Zellwerk GmbH in Germany and Dualsystems Biotech AG in Switzerland. Zellwerk GmbH isolated T-cells and coupled the ligands to TriCEPSTM. Zellwerk GmbH added then the TriCEPSTM coupled ligands to the cells, froze the cells and sent it to Dualsystems. In the presented experiment anti-CD28 antibodies were used as positive control and anti-TCR2alpha/beta antibodies were used as Ligand of Interest. The two expected targets CD28 and T-cell receptor beta chain 1(TRBC1) could be clearly identified.
For further information or to obtain a quote to perform a LRC-TriCEPSTM (Ligand-Receptor capture) experiments on primary cells please contact